Spok Holdings, Inc.
Spok Holdings, Inc. (SPOK) Stock Competitors & Peer Comparison
See (SPOK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SPOK | $11.78 | -1.67% | 244.2M | 15.71 | $0.75 | +10.64% |
| GEHC | $70.77 | +0.63% | 32.3B | 15.55 | $4.55 | +0.20% |
| VEEV | $178.88 | -1.06% | 29.4B | 32.88 | $5.44 | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $128.36 | -1.13% | 24.8B | N/A | N/A | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| TEM | $49.98 | +0.91% | 8.6B | -35.45 | -$1.41 | N/A |
| BTSG | $38.31 | -0.85% | 7.4B | 79.81 | $0.48 | N/A |
| HQY | $77.81 | +1.33% | 6.7B | 35.69 | $2.18 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
SPOK vs GEHC Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, GEHC has a market cap of 32.3B. Regarding current trading prices, SPOK is priced at $11.78, while GEHC trades at $70.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas GEHC's P/E ratio is 15.55. In terms of profitability, SPOK's ROE is +0.11%, compared to GEHC's ROE of +0.17%. Regarding short-term risk, SPOK is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check GEHC's competition here
SPOK vs VEEV Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, VEEV has a market cap of 29.4B. Regarding current trading prices, SPOK is priced at $11.78, while VEEV trades at $178.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas VEEV's P/E ratio is 32.88. In terms of profitability, SPOK's ROE is +0.11%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SPOK is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check VEEV's competition here
SPOK vs GEHCV Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SPOK is priced at $11.78, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to GEHCV's ROE of +0.21%. Regarding short-term risk, SPOK is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check GEHCV's competition here
SPOK vs BTSGU Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BTSGU has a market cap of 24.8B. Regarding current trading prices, SPOK is priced at $11.78, while BTSGU trades at $128.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BTSGU's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to BTSGU's ROE of +0.11%. Regarding short-term risk, SPOK is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check BTSGU's competition here
SPOK vs SGFY Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SPOK is priced at $11.78, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SPOK's ROE is +0.11%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SPOK is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SGFY's competition here
SPOK vs TEM Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, TEM has a market cap of 8.6B. Regarding current trading prices, SPOK is priced at $11.78, while TEM trades at $49.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas TEM's P/E ratio is -35.45. In terms of profitability, SPOK's ROE is +0.11%, compared to TEM's ROE of -0.60%. Regarding short-term risk, SPOK is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check TEM's competition here
SPOK vs BTSG Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BTSG has a market cap of 7.4B. Regarding current trading prices, SPOK is priced at $11.78, while BTSG trades at $38.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BTSG's P/E ratio is 79.81. In terms of profitability, SPOK's ROE is +0.11%, compared to BTSG's ROE of +0.11%. Regarding short-term risk, SPOK is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check BTSG's competition here
SPOK vs HQY Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HQY has a market cap of 6.7B. Regarding current trading prices, SPOK is priced at $11.78, while HQY trades at $77.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HQY's P/E ratio is 35.69. In terms of profitability, SPOK's ROE is +0.11%, compared to HQY's ROE of +0.09%. Regarding short-term risk, SPOK is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check HQY's competition here
SPOK vs RCM Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SPOK is priced at $11.78, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas RCM's P/E ratio is -102.21. In terms of profitability, SPOK's ROE is +0.11%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SPOK is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check RCM's competition here
SPOK vs DOCS Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, DOCS has a market cap of 4.6B. Regarding current trading prices, SPOK is priced at $11.78, while DOCS trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas DOCS's P/E ratio is 20.47. In terms of profitability, SPOK's ROE is +0.11%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, SPOK is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check DOCS's competition here
SPOK vs HNGE Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HNGE has a market cap of 3.5B. Regarding current trading prices, SPOK is priced at $11.78, while HNGE trades at $45.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HNGE's P/E ratio is -5.86. In terms of profitability, SPOK's ROE is +0.11%, compared to HNGE's ROE of -1.32%. Regarding short-term risk, SPOK is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check HNGE's competition here
SPOK vs ONEM Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SPOK is priced at $11.78, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SPOK's ROE is +0.11%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SPOK is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check ONEM's competition here
SPOK vs PRVA Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, PRVA has a market cap of 2.7B. Regarding current trading prices, SPOK is priced at $11.78, while PRVA trades at $21.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas PRVA's P/E ratio is 120.44. In terms of profitability, SPOK's ROE is +0.11%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, SPOK is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check PRVA's competition here
SPOK vs TXG Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, TXG has a market cap of 2.4B. Regarding current trading prices, SPOK is priced at $11.78, while TXG trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas TXG's P/E ratio is -53.69. In terms of profitability, SPOK's ROE is +0.11%, compared to TXG's ROE of -0.06%. Regarding short-term risk, SPOK is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check TXG's competition here
SPOK vs PINC Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, SPOK is priced at $11.78, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas PINC's P/E ratio is 166.24. In terms of profitability, SPOK's ROE is +0.11%, compared to PINC's ROE of -0.02%. Regarding short-term risk, SPOK is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check PINC's competition here
SPOK vs WGS Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, SPOK is priced at $11.78, while WGS trades at $77.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas WGS's P/E ratio is -106.55. In terms of profitability, SPOK's ROE is +0.11%, compared to WGS's ROE of -0.07%. Regarding short-term risk, SPOK is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check WGS's competition here
SPOK vs HTFL Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HTFL has a market cap of 1.7B. Regarding current trading prices, SPOK is priced at $11.78, while HTFL trades at $20.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HTFL's P/E ratio is -13.66. In terms of profitability, SPOK's ROE is +0.11%, compared to HTFL's ROE of +0.18%. Regarding short-term risk, SPOK is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check HTFL's competition here
SPOK vs NXGN Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SPOK is priced at $11.78, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SPOK's ROE is +0.11%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SPOK is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check NXGN's competition here
SPOK vs OMCL Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, OMCL has a market cap of 1.6B. Regarding current trading prices, SPOK is priced at $11.78, while OMCL trades at $34.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas OMCL's P/E ratio is 860.00. In terms of profitability, SPOK's ROE is +0.11%, compared to OMCL's ROE of +0.00%. Regarding short-term risk, SPOK is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check OMCL's competition here
SPOK vs PGNY Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, PGNY has a market cap of 1.4B. Regarding current trading prices, SPOK is priced at $11.78, while PGNY trades at $17.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas PGNY's P/E ratio is 26.92. In terms of profitability, SPOK's ROE is +0.11%, compared to PGNY's ROE of +0.11%. Regarding short-term risk, SPOK is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check PGNY's competition here
SPOK vs AGTI Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SPOK is priced at $11.78, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SPOK's ROE is +0.11%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SPOK is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check AGTI's competition here
SPOK vs CERT Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CERT has a market cap of 1.1B. Regarding current trading prices, SPOK is priced at $11.78, while CERT trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CERT's P/E ratio is -665.00. In terms of profitability, SPOK's ROE is +0.11%, compared to CERT's ROE of -0.00%. Regarding short-term risk, SPOK is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check CERT's competition here
SPOK vs TDOC Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, TDOC has a market cap of 959.8M. Regarding current trading prices, SPOK is priced at $11.78, while TDOC trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas TDOC's P/E ratio is -4.72. In terms of profitability, SPOK's ROE is +0.11%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, SPOK is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check TDOC's competition here
SPOK vs SDGR Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SDGR has a market cap of 923.6M. Regarding current trading prices, SPOK is priced at $11.78, while SDGR trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SDGR's P/E ratio is -8.87. In terms of profitability, SPOK's ROE is +0.11%, compared to SDGR's ROE of -0.29%. Regarding short-term risk, SPOK is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SDGR's competition here
SPOK vs OMDA Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, OMDA has a market cap of 841.4M. Regarding current trading prices, SPOK is priced at $11.78, while OMDA trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas OMDA's P/E ratio is -33.02. In terms of profitability, SPOK's ROE is +0.11%, compared to OMDA's ROE of -0.07%. Regarding short-term risk, SPOK is less volatile compared to OMDA. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check OMDA's competition here
SPOK vs CCLDO Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CCLDO has a market cap of 804.8M. Regarding current trading prices, SPOK is priced at $11.78, while CCLDO trades at $25.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to CCLDO's ROE of +0.19%. Regarding short-term risk, SPOK is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check CCLDO's competition here
SPOK vs GDRX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, GDRX has a market cap of 767.6M. Regarding current trading prices, SPOK is priced at $11.78, while GDRX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas GDRX's P/E ratio is 24.89. In terms of profitability, SPOK's ROE is +0.11%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, SPOK is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check GDRX's competition here
SPOK vs PHR Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, PHR has a market cap of 661.3M. Regarding current trading prices, SPOK is priced at $11.78, while PHR trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas PHR's P/E ratio is -121.89. In terms of profitability, SPOK's ROE is +0.11%, compared to PHR's ROE of -0.02%. Regarding short-term risk, SPOK is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check PHR's competition here
SPOK vs MPLN-WT Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SPOK is priced at $11.78, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to MPLN-WT's ROE of +3.78%. Regarding short-term risk, SPOK is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check MPLN-WT's competition here
SPOK vs HSTM Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HSTM has a market cap of 602.3M. Regarding current trading prices, SPOK is priced at $11.78, while HSTM trades at $20.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HSTM's P/E ratio is 33.28. In terms of profitability, SPOK's ROE is +0.11%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, SPOK is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check HSTM's competition here
SPOK vs ACCD Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SPOK is priced at $11.78, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SPOK's ROE is +0.11%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SPOK is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check ACCD's competition here
SPOK vs SHCR Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SPOK is priced at $11.78, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SPOK's ROE is +0.11%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SPOK is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SHCR's competition here
SPOK vs NUTX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, NUTX has a market cap of 528.7M. Regarding current trading prices, SPOK is priced at $11.78, while NUTX trades at $88.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas NUTX's P/E ratio is 9.05. In terms of profitability, SPOK's ROE is +0.11%, compared to NUTX's ROE of +0.24%. Regarding short-term risk, SPOK is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check NUTX's competition here
SPOK vs SY Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SY has a market cap of 403M. Regarding current trading prices, SPOK is priced at $11.78, while SY trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SY's P/E ratio is -2.90. In terms of profitability, SPOK's ROE is +0.11%, compared to SY's ROE of -0.42%. Regarding short-term risk, SPOK is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check SY's competition here
SPOK vs SLGCW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SPOK is priced at $11.78, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SPOK's ROE is +0.11%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SPOK is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check SLGCW's competition here
SPOK vs SLGC Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SPOK is priced at $11.78, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SPOK's ROE is +0.11%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SPOK is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check SLGC's competition here
SPOK vs MPLN Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SPOK is priced at $11.78, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SPOK's ROE is +0.11%, compared to MPLN's ROE of +3.78%. Regarding short-term risk, SPOK is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check MPLN's competition here
SPOK vs NRC Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, NRC has a market cap of 374.3M. Regarding current trading prices, SPOK is priced at $11.78, while NRC trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas NRC's P/E ratio is 33.04. In terms of profitability, SPOK's ROE is +0.11%, compared to NRC's ROE of +0.59%. Regarding short-term risk, SPOK is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check NRC's competition here
SPOK vs EVH Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, EVH has a market cap of 332.7M. Regarding current trading prices, SPOK is priced at $11.78, while EVH trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas EVH's P/E ratio is -0.59. In terms of profitability, SPOK's ROE is +0.11%, compared to EVH's ROE of -0.69%. Regarding short-term risk, SPOK is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check EVH's competition here
SPOK vs SOPH Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SOPH has a market cap of 312.8M. Regarding current trading prices, SPOK is priced at $11.78, while SOPH trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SOPH's P/E ratio is -3.94. In terms of profitability, SPOK's ROE is +0.11%, compared to SOPH's ROE of -1.17%. Regarding short-term risk, SPOK is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SOPH's competition here
SPOK vs CARL Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CARL has a market cap of 304.7M. Regarding current trading prices, SPOK is priced at $11.78, while CARL trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CARL's P/E ratio is -5.38. In terms of profitability, SPOK's ROE is +0.11%, compared to CARL's ROE of -2.64%. Regarding short-term risk, SPOK is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check CARL's competition here
SPOK vs TRHC Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SPOK is priced at $11.78, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SPOK's ROE is +0.11%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SPOK is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check TRHC's competition here
SPOK vs CTEV Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CTEV has a market cap of 279.7M. Regarding current trading prices, SPOK is priced at $11.78, while CTEV trades at $16.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CTEV's P/E ratio is -0.98. In terms of profitability, SPOK's ROE is +0.11%, compared to CTEV's ROE of +3.78%. Regarding short-term risk, SPOK is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check CTEV's competition here
SPOK vs TBRG Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, TBRG has a market cap of 259.8M. Regarding current trading prices, SPOK is priced at $11.78, while TBRG trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas TBRG's P/E ratio is 72.13. In terms of profitability, SPOK's ROE is +0.11%, compared to TBRG's ROE of +0.03%. Regarding short-term risk, SPOK is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check TBRG's competition here
SPOK vs SLP Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SLP has a market cap of 250.6M. Regarding current trading prices, SPOK is priced at $11.78, while SLP trades at $12.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SLP's P/E ratio is -3.89. In terms of profitability, SPOK's ROE is +0.11%, compared to SLP's ROE of -0.45%. Regarding short-term risk, SPOK is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SLP's competition here
SPOK vs SMFR Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SPOK is priced at $11.78, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SMFR's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to SMFR's ROE of -0.07%. Regarding short-term risk, SPOK is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check SMFR's competition here
SPOK vs CPSI Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SPOK is priced at $11.78, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SPOK's ROE is +0.11%, compared to CPSI's ROE of -0.05%. Regarding short-term risk, SPOK is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check CPSI's competition here
SPOK vs CCLD Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CCLD has a market cap of 133.1M. Regarding current trading prices, SPOK is priced at $11.78, while CCLD trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CCLD's P/E ratio is 44.86. In terms of profitability, SPOK's ROE is +0.11%, compared to CCLD's ROE of +0.19%. Regarding short-term risk, SPOK is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check CCLD's competition here
SPOK vs OPRX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, OPRX has a market cap of 119.3M. Regarding current trading prices, SPOK is priced at $11.78, while OPRX trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas OPRX's P/E ratio is 640.00. In terms of profitability, SPOK's ROE is +0.11%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, SPOK is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check OPRX's competition here
SPOK vs DH Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, DH has a market cap of 118.1M. Regarding current trading prices, SPOK is priced at $11.78, while DH trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas DH's P/E ratio is -0.87. In terms of profitability, SPOK's ROE is +0.11%, compared to DH's ROE of -0.47%. Regarding short-term risk, SPOK is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check DH's competition here
SPOK vs AUGX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SPOK is priced at $11.78, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SPOK's ROE is +0.11%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SPOK is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check AUGX's competition here
SPOK vs HCAT Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HCAT has a market cap of 93.4M. Regarding current trading prices, SPOK is priced at $11.78, while HCAT trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HCAT's P/E ratio is -0.84. In terms of profitability, SPOK's ROE is +0.11%, compared to HCAT's ROE of -0.55%. Regarding short-term risk, SPOK is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check HCAT's competition here
SPOK vs AMWL Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, AMWL has a market cap of 92.9M. Regarding current trading prices, SPOK is priced at $11.78, while AMWL trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas AMWL's P/E ratio is -0.88. In terms of profitability, SPOK's ROE is +0.11%, compared to AMWL's ROE of -0.36%. Regarding short-term risk, SPOK is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check AMWL's competition here
SPOK vs FORA Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, FORA has a market cap of 63.7M. Regarding current trading prices, SPOK is priced at $11.78, while FORA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas FORA's P/E ratio is -102.50. In terms of profitability, SPOK's ROE is +0.11%, compared to FORA's ROE of -0.03%. Regarding short-term risk, SPOK is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check FORA's competition here
SPOK vs CCLDP Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SPOK is priced at $11.78, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to CCLDP's ROE of +0.19%. Regarding short-term risk, SPOK is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check CCLDP's competition here
SPOK vs BEAT Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BEAT has a market cap of 46.8M. Regarding current trading prices, SPOK is priced at $11.78, while BEAT trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BEAT's P/E ratio is -2.06. In terms of profitability, SPOK's ROE is +0.11%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, SPOK is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check BEAT's competition here
SPOK vs SNCE Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SPOK is priced at $11.78, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SPOK's ROE is +0.11%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SPOK is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SNCE's competition here
SPOK vs AKLI Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SPOK is priced at $11.78, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SPOK's ROE is +0.11%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SPOK is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check AKLI's competition here
SPOK vs SHLT Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SPOK is priced at $11.78, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SPOK's ROE is +0.11%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SPOK is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check SHLT's competition here
SPOK vs SHCRW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SPOK is priced at $11.78, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SPOK's ROE is +0.11%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SPOK is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check SHCRW's competition here
SPOK vs ONMD Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ONMD has a market cap of 28.4M. Regarding current trading prices, SPOK is priced at $11.78, while ONMD trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ONMD's P/E ratio is -14.43. In terms of profitability, SPOK's ROE is +0.11%, compared to ONMD's ROE of +0.20%. Regarding short-term risk, SPOK is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check ONMD's competition here
SPOK vs STRM Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SPOK is priced at $11.78, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas STRM's P/E ratio is -2.40. In terms of profitability, SPOK's ROE is +0.11%, compared to STRM's ROE of -0.50%. Regarding short-term risk, SPOK is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check STRM's competition here
SPOK vs RNLX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SPOK is priced at $11.78, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SPOK's ROE is +0.11%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SPOK is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check RNLX's competition here
SPOK vs LIFW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SPOK is priced at $11.78, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SPOK's ROE is +0.11%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, SPOK is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check LIFW's competition here
SPOK vs EUDA Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, EUDA has a market cap of 18.5M. Regarding current trading prices, SPOK is priced at $11.78, while EUDA trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas EUDA's P/E ratio is 24.53. In terms of profitability, SPOK's ROE is +0.11%, compared to EUDA's ROE of -0.09%. Regarding short-term risk, SPOK is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check EUDA's competition here
SPOK vs BBLN Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SPOK is priced at $11.78, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SPOK's ROE is +0.11%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SPOK is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check BBLN's competition here
SPOK vs ETAO Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SPOK is priced at $11.78, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SPOK's ROE is +0.11%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SPOK is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check ETAO's competition here
SPOK vs SCNX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, SCNX has a market cap of 7.2M. Regarding current trading prices, SPOK is priced at $11.78, while SCNX trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas SCNX's P/E ratio is 0.62. In terms of profitability, SPOK's ROE is +0.11%, compared to SCNX's ROE of -0.26%. Regarding short-term risk, SPOK is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check SCNX's competition here
SPOK vs HLTH Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SPOK is priced at $11.78, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SPOK's ROE is +0.11%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SPOK is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check HLTH's competition here
SPOK vs BFRG Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BFRG has a market cap of 6M. Regarding current trading prices, SPOK is priced at $11.78, while BFRG trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BFRG's P/E ratio is -0.90. In terms of profitability, SPOK's ROE is +0.11%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, SPOK is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check BFRG's competition here
SPOK vs ZCMD Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ZCMD has a market cap of 5.8M. Regarding current trading prices, SPOK is priced at $11.78, while ZCMD trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ZCMD's P/E ratio is -1.19. In terms of profitability, SPOK's ROE is +0.11%, compared to ZCMD's ROE of -0.08%. Regarding short-term risk, SPOK is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check ZCMD's competition here
SPOK vs UPH Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SPOK is priced at $11.78, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas UPH's P/E ratio is -0.07. In terms of profitability, SPOK's ROE is +0.11%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SPOK is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check UPH's competition here
SPOK vs BEATW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BEATW has a market cap of 5M. Regarding current trading prices, SPOK is priced at $11.78, while BEATW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BEATW's P/E ratio is -0.29. In terms of profitability, SPOK's ROE is +0.11%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, SPOK is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check BEATW's competition here
SPOK vs VSEE Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, VSEE has a market cap of 4.6M. Regarding current trading prices, SPOK is priced at $11.78, while VSEE trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas VSEE's P/E ratio is 0.61. In terms of profitability, SPOK's ROE is +0.11%, compared to VSEE's ROE of +3.37%. Regarding short-term risk, SPOK is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check VSEE's competition here
SPOK vs MGRX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, MGRX has a market cap of 4.2M. Regarding current trading prices, SPOK is priced at $11.78, while MGRX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas MGRX's P/E ratio is -0.13. In terms of profitability, SPOK's ROE is +0.11%, compared to MGRX's ROE of -1.15%. Regarding short-term risk, SPOK is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check MGRX's competition here
SPOK vs PEARW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SPOK is priced at $11.78, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SPOK's ROE is +0.11%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SPOK is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check PEARW's competition here
SPOK vs PEAR Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SPOK is priced at $11.78, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SPOK's ROE is +0.11%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SPOK is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check PEAR's competition here
SPOK vs OTRK Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SPOK is priced at $11.78, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SPOK's ROE is +0.11%, compared to OTRK's ROE of -2.04%. Regarding short-term risk, SPOK is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check OTRK's competition here
SPOK vs BFRGW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, BFRGW has a market cap of 2.2M. Regarding current trading prices, SPOK is priced at $11.78, while BFRGW trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas BFRGW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, SPOK is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check BFRGW's competition here
SPOK vs ACON Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ACON has a market cap of 1.9M. Regarding current trading prices, SPOK is priced at $11.78, while ACON trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ACON's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to ACON's ROE of -0.68%. Regarding short-term risk, SPOK is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check ACON's competition here
SPOK vs VSEEW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, VSEEW has a market cap of 1.8M. Regarding current trading prices, SPOK is priced at $11.78, while VSEEW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas VSEEW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to VSEEW's ROE of +3.37%. Regarding short-term risk, SPOK is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check VSEEW's competition here
SPOK vs EUDAW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, EUDAW has a market cap of 1.6M. Regarding current trading prices, SPOK is priced at $11.78, while EUDAW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas EUDAW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to EUDAW's ROE of -0.09%. Regarding short-term risk, SPOK is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check EUDAW's competition here
SPOK vs CMAX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SPOK is priced at $11.78, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CMAX's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SPOK is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check CMAX's competition here
SPOK vs LIFWZ Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SPOK is priced at $11.78, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, SPOK is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check LIFWZ's competition here
SPOK vs WORX Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, WORX has a market cap of 575.8K. Regarding current trading prices, SPOK is priced at $11.78, while WORX trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas WORX's P/E ratio is -0.17. In terms of profitability, SPOK's ROE is +0.11%, compared to WORX's ROE of -0.72%. Regarding short-term risk, SPOK is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check WORX's competition here
SPOK vs MSPRZ Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SPOK is priced at $11.78, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, SPOK is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check MSPRZ's competition here
SPOK vs MSPR Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, MSPR has a market cap of 399.5K. Regarding current trading prices, SPOK is priced at $11.78, while MSPR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas MSPR's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, SPOK is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check MSPR's competition here
SPOK vs HCTI Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, HCTI has a market cap of 280.9K. Regarding current trading prices, SPOK is priced at $11.78, while HCTI trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas HCTI's P/E ratio is -0.03. In terms of profitability, SPOK's ROE is +0.11%, compared to HCTI's ROE of -1.13%. Regarding short-term risk, SPOK is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check HCTI's competition here
SPOK vs WGSWW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, WGSWW has a market cap of 232K. Regarding current trading prices, SPOK is priced at $11.78, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas WGSWW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to WGSWW's ROE of -0.07%. Regarding short-term risk, SPOK is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check WGSWW's competition here
SPOK vs KERN Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SPOK is priced at $11.78, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas KERN's P/E ratio is -0.01. In terms of profitability, SPOK's ROE is +0.11%, compared to KERN's ROE of -0.03%. Regarding short-term risk, SPOK is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check KERN's competition here
SPOK vs KERNW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SPOK is priced at $11.78, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SPOK's ROE is +0.11%, compared to KERNW's ROE of -0.03%. Regarding short-term risk, SPOK is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check KERNW's competition here
SPOK vs LIFWW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SPOK is priced at $11.78, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, SPOK is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check LIFWW's competition here
SPOK vs OTRKP Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, SPOK is priced at $11.78, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, SPOK's ROE is +0.11%, compared to OTRKP's ROE of -2.04%. Regarding short-term risk, SPOK is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check OTRKP's competition here
SPOK vs CMAXW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SPOK is priced at $11.78, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SPOK is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check CMAXW's competition here
SPOK vs ACONW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ACONW has a market cap of 23.3K. Regarding current trading prices, SPOK is priced at $11.78, while ACONW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ACONW's P/E ratio is -0.01. In terms of profitability, SPOK's ROE is +0.11%, compared to ACONW's ROE of -0.68%. Regarding short-term risk, SPOK is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check ACONW's competition here
SPOK vs ICCT Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, ICCT has a market cap of 9.8K. Regarding current trading prices, SPOK is priced at $11.78, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas ICCT's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to ICCT's ROE of +2.42%. Regarding short-term risk, SPOK is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check ICCT's competition here
SPOK vs MSPRW Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, MSPRW has a market cap of 4.1K. Regarding current trading prices, SPOK is priced at $11.78, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas MSPRW's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, Volatility data is not available for a full comparison. SPOK has daily volatility of 4.27 and MSPRW has daily volatility of N/A.Check MSPRW's competition here
SPOK vs FOXO Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, SPOK is priced at $11.78, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas FOXO's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to FOXO's ROE of -0.80%. Regarding short-term risk, SPOK is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for SPOK.Check FOXO's competition here
SPOK vs UTRS Comparison March 2026
SPOK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SPOK stands at 244.2M. In comparison, UTRS has a market cap of 888. Regarding current trading prices, SPOK is priced at $11.78, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SPOK currently has a P/E ratio of 15.71, whereas UTRS's P/E ratio is N/A. In terms of profitability, SPOK's ROE is +0.11%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, SPOK is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for SPOK.Check UTRS's competition here